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Objective: To evaluate the association between radiographic osteoarthritis (OA) and either serum insulin-
like growth factor-1 (IGF-1) levels or IGF-1 gene polymorphisms in patients with primary OA.
Methods: We conducted a systematic review of reported associations between circulating IGF-1 and/or
IGF-1 gene polymorphisms and radiographic OA. Studies were eligible when: (1) investigating serum
IGF-1 and/or IGF-1 gene polymorphisms in relation to prevalent or incident radiographic OA; (2) written
in English; (3) full-text article or abstract; (4) patients had primary OA in knee, hip, hand or spine; (5)
longitudinal, case-control or cross-sectional design. Quality assessment was done using a standardized
criteria set. Best-evidence synthesis was performed based on guidelines on systematic review from the
Cochrane Collaboration Back Review Group, using ﬁve evidence levels: strong, moderate, limited, con-
ﬂicting and no evidence.
Results: We included 11 studies with more than 3000 primary OA cases. Data on the relationship
between serum IGF-1 and radiographic OAwere inconsistent. Adjustment for body mass index (BMI) was
often omitted. Of four high-quality studies, three studies reported no association, one study found
signiﬁcantly higher IGF-1 levels in OA patients compared to controls. Patients with IGF-1 gene promoter
polymorphisms and a genetic variation at the IGF-1R locus had an increased OA prevalence compared to
controls.
Conclusions: Observational data showed no association between serum IGF-1 and occurrence of radio-
graphic OA (moderate level of evidence), and a positive relationship between IGF-1 gene polymorphisms
and radiographic OA (moderate level of evidence); however the confounding effect of BMI was insufﬁ-
ciently addressed. Future well-designed prospective studies should further elaborate the role of the
complex GH/IGF-1 system in primary OA.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is a common disease, characterized by
progressive degradation of articular cartilage and bone remodeling,
resulting in pain and disability. Despite the increase in molecular
knowledge accrued during the last years, the exact pathogenesis of
the destructive process remains unknown. OA is considered to be
a multifactorial disease in which age, body mass index (BMI),
hormonal and local biomechanical factors together with genetic
predisposition play a role1e5. In OA, the stable equilibrium between
synthesis and breakdown of cartilage components is disrupted andM.J.A. Claessen, Department of
versityMedical Center, POBox
6896; Fax: 31-71-5248136.
. Claessen).
ork.
s Research Society International. Pthe rate of loss of proteoglycans and other matrix components
eventually exceeds their formation rate6. Factors responsible for
preservation or loss of the articular cartilage matrix are of consid-
erable interest to clinicians and scientists. Among chondrotrophic
growth factors, insulin-like growth factor-1 (IGF-1) and its
response on mature adult cartilage have been studied extensively.
IGF-1 is an important growth promoting peptide with structural
and functional homology to pro-insulin. IGF-1 is mainly produced
by the liver and mediates the effects of growth hormone (GH) at
tissue level. In addition, IGF-1 is a key factor for longitudinal skel-
etal growth7. Serum IGF-1 concentrations in adulthood decrease
progressively with age and are inﬂuenced by many other factors,
such as BMI8,9. Three lines of research suggest IGF-1 involvement in
OA pathogenesis. Firstly, IGF-1 has been shown to enhance chon-
drocyte proliferation and proteoglycan and collagen synthesis by
chondrocytes in normal cartilage, both in vivo and in vitro10e20,
also during cytokine exposure, which drives most predominatingublished by Elsevier Ltd. All rights reserved.
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cytokine-stimulated degradation of proteoglycans directly in
normal cartilage in vitro21,22. These anabolic and protecting prop-
erties make IGF-1 an obvious candidate for a major role in cartilage
repair.
Secondly, serum IGF-1 is elevated in acromegaly, a rare endo-
crine disease caused by GH overproduction from a pituitary
adenoma. The GH excess results in high serum GH and IGF-1 levels
and is associated with an increased risk of secondary OA23,24.
Prevalence and severity of arthropathy worsenwith the duration of
uncontrolled acromegaly. Furthermore, pre-treatment IGF-1 levels
predict radiographic OA in a dose-dependent manner25.
Finally, earlier studies showed that genes regulating formation,
degradation and repair of articular cartilage and subchondral bone
remodeling may be involved in OA pathogenesis26e29. Probably,
genetic variations of GH/IGF-1 genes with functional properties
may affect the pathogenesis of primary OA.
Several epidemiological studies have explored the role of serum
IGF-1 in primary OA, showing various results30e33. We aimed to
systematically review observational studies on the relationship
between radiographic OA and either serum IGF-1 or IGF-1 gene
polymorphisms in patients with primary OA, taking into account
the variable quality of studies.
Materials and methods
Identiﬁcation and selection of the literature
To identify studies investigating the relationship between IGF-1
and radiographic primary OA, we searched the following databases,
up to May 2011: Medline, EMBASE, Web of Science, the Cochrane
Library, ScienceDirect, CINAHL, LWW Journals, Wiley, Academic
Search Premier and WHO International Clinical Trials Registration
Platform. The following combined key words were used: (“Insulin-
Like Growth Factor I” OR “IGF-1” OR “Insulin-Like Somatomedin
Peptide I” OR “Somatomedin C” OR “IGF-I-SmC” OR “Receptor, IGF
Type 1” OR “IGF-1 Receptor” OR “IGF 1 Receptor” OR “IGF-I
Receptor” OR “IGF I Receptor” OR “IGF-1 Receptors” OR “IGF Type 1
Receptor” OR “Insulin-Like-Growth Factor I Receptor”) AND
(“Osteoarthritis” OR “Osteoarthritides” OR “Osteoarthrosis” ORTable I
List of criteria used for methodological quality assessment
Item Criterion
Study population
1. Clear description of selectio
2. Sufﬁcient description of ch
3. Cases and controls were dr
4. Participation rate 80% for
5. Participation rate 80% for
Assessment of risk factor:
serum IGF-1 levels/IGF-1
gene polymorphism
6. Serum IGF-1/IGF-1 gene po
with standardized or valid
7. IGF-1 measurement/IGF-1
was identical in the studied
Radiographic OA assessment
8. Radiographic OA measures
9. Presence of radiographic O
10. Radiographic OA was asses
Analysis and data presentation
11. Mean levels of IGF-1 (e.g.,
12. Frequencies of radiographi
13. Appropriate analysis techn
14. Adjusted for at least age, se
* Applicable to CH ¼ cohort study; CC ¼ case-control study; CS ¼ cross-sectional stud“Osteoarthroses” OR “Degenerative Arthritides” OR “Degenerative
Arthritis”). References of relevant articles were checked for addi-
tional articles.
A study was eligible for inclusion with the following criteria: (1)
the association between serum IGF-1 levels and/or IGF-1 gene
polymorphisms and prevalent or incident radiographic OA was
investigated; (2) written in English; (3) full-text article or abstract;
(4) patients had primary OA in knee, hip, hand or spine; (5)
longitudinal, case-control or cross-sectional design. Incident OA
was deﬁned as the development of OA in joints that were previ-
ously unaffected during the speciﬁed time period in a longitudinal
study. Prevalent OA was deﬁned as the presence of OA at the
moment of the study visit in a cross-sectional or case-control study.
A study was excluded if the studied population had a speciﬁc
underlying pathology, such as trauma (fractures), infection, rheu-
matoid arthritis, or ankylosing spondylitis. Only human studies
were evaluated.Data extraction and analysis
Data extraction and eligibility were assessed by two indepen-
dent investigators (KMJAC and SRR). Inconsistencies in data
extraction were resolved by consensus. We used data comparing
serum IGF-1 and/or presence of IGF-1 gene polymorphisms
between patients with radiographic OA and controls without
radiographic OA.
The following data were extracted: (1) study population
(patient characteristics, population size, gender, age, BMI); (2) expo-
sure (serum IGF-1 or IGF-1 gene polymorphisms); (3) outcome
(methods of assessment of radiographic OA, reproducibility, blind-
ing); (4) potential confounders (age, sex, BMI, height, race).Methodological quality assessment
The quality of each included paper was assessed by two inde-
pendent reviewers (KMJAC and SRR) using a standardized set of
criteria (Table I), which have been used previously in reviews on
musculoskeletal disorders34 and were modiﬁed to cover the topic
of our review.CH/CC/CS/GA*
n of study subjects. CH/CC/CS/GA
aracteristics of study groups. CH/CC/CS/GA
awn from the same source population. CC
cases/cohort. CH/CC/CS/GA
controls. CC
lymorphism was assessed
instruments.
CH/CC/CS/GA
gene polymorphism assessment
population.
CH/CC/CS/GA
were valid. CH/CC/CS/GA
A was assessed reproducibly. CH/CC/CS/GA
sed identically in all patients. CH/CC/CS/GA
serum and/or synovial) were given. CH/CC/CS
c OA were given. CH/CCCS/GA
iques were used. CH/CC/CS/GA
x and BMI. CH/CC/CS/GA
y; GA ¼ genetic association study.
668 potentially relevant publications 
identified  from electronic search
34 publications retrieved for more 
detailed assessment
634 studies excluded based on title and 
abstract
23 articles did not fulfill the inclusion 
criteria because of the following   
reasons:
  7 articles: no primary OA
10 articles: no radiographic OA
  3 articles: review article
K.M.J.A. Claessen et al. / Osteoarthritis and Cartilage 20 (2012) 79e86 81When the criterion was met in the article, ‘1’ was given, other-
wise ‘0’. A ‘0’ was also given when no information was given about
the speciﬁc criterion mentioned in the article. Several items are not
applicable to certain types of study design and therefore do not
contribute to the total score of that particular study. The maximum
score (100%) for each study was based only on the items applicable
to that particular study design (cohort and case-control 14, cross-
sectional 11). Total scores per study were calculated as the
percentage of maximum obtainable scores. For example, a quality
score of 57% (8/14  100%) was assigned to a case-control study
with eight positive items. A studywas considered high-quality (HQ)
if the methodological quality score was 64%, chosen as the
median of all quality scores.11 studies eligible for inclusion
   1 article: duplicate of full text article
 2 articles: OA severity or progression 
Fig. 1. Flow diagram of study selection and exclusion stages.Level of evidence synthesis
Because the observational studies were heterogeneous with
regard to study population, methodological quality and determi-
nants and measures of radiological OA assessment, we followed
standard practice and refrained from statistically pooling the data
and performed a ‘best-evidence’ synthesis. A prospective cohort
study was judged as the preferred design, followed by a case-
control study, and then by a cross-sectional study. Subsequently,
the studies were ranked according to their methodological quality
score. The following ranking of the levels of evidence was formu-
lated based on the guidelines on systematic review of the Cochrane
Collaboration Back Review Group, a method to summarize
evidence in observation studies with heterogeneous methodolog-
ical study characteristics (Table II)35,36.
Sensitivity analyses by deﬁning other cut-offs (mean score of all
studies instead of median) of HQ studies were performed.
Furthermore, a sensitivity analysis was performed based on all
positive studies, regardless of methodological quality. A study was
regarded as positive if it showed a signiﬁcant association between
serum IGF-1 and radiographic OA.Results
Identiﬁcation and selection of the literature
From initial 668 potentially relevant studies identiﬁed, 634
were excluded on the basis of title and abstract. 34 papers were
retrieved for detailed assessment: seven were excluded because
no primary OA patients were included, 10 because OA was not
assessed radiographically, and three were not original articles. One
abstract appeared to be a duplicate of a full-text article and was
excluded. Another two studies were excluded because they
studied OA progression and severity, respectively, and not preva-
lent or incident OA. Consequently, a total of 11 studies were
included (Fig. 1).Table II
Levels of evidence used in best-evidence synthesis
Strong Generally consistent ﬁndings were presented in multiple
HQ cohort studies.
Moderate One HQ cohort study and two or more HQ case-control
studies, or when at least three HQ case-control studies
show generally consistent results.
Limited Generally consistent ﬁndings were found in a single
cohort study, or in one or two case-control studies
or in multiple cross-sectional studies.
Conﬂicting Less than 75% of the studies reported consistent ﬁndings.
No evidence No study could be found.Study description
A detailed study description is given in Tables IIIa and b. These
studies provided data on the relationship between serum IGF-1 and
radiographic OA of knee (n ¼ 5)30,33,37,38,40, hand (n ¼ 1)32, OA in
general (n ¼ 3)31,39, and IGF-1 gene polymorphisms (n ¼ 3)26e28.
The studies were published from 1992 onwards. One had a nested
case-control design; the other 10 were case-control/cross-sectional
studies. All studies used a radio-immuno assay (RIA) for IGF-1
measurement in serum. Assays were generally done blinded to
case status.
Most studies investigated a middle-aged population and three
exclusively included women31,32,40. The majority of studies
adjusted for age and sex, two studies were matched30,39. Three
studies adjusted for at least three variables26,28,38.
Six studies assessed radiographic OA according to the Kellgren &
Lawrence (KL) score, and two studies used personal scoring
systems for individual radiographic OA features (individual score
by Scott et al.,33 individual score by the principles of KL30). Two
studies used both KL and a scoring method for individual OA
characteristics. Two studies also assessed clinical OA; one by the
American College of Rheumatology criteria (ACR) criteria for knee
OA37, the other used a question about knee pain from the Health
and Nutrition Examination Survey30.
Methodological quality assessment
The quality of studies was assessed according to the criteria
stated in Table I and methodological quality scores are shown in
Table IV. The scores ranged from 14% to 82% of the maximum
obtainable score for each study design, with a median score of
64%. Only four of the eight studies on serum IGF-1 and radio-
graphic OA (one cohort study, three case-control/cross-sectional
studies) and all three studies on IGF-1 gene polymorphisms
were HQ studies.
Overall, selection of study subjects was not clearly described.
In addition, none of studies described participation rates for cases
and controls in detail. Reproducibility of radiological OA scoring
was described in only three studies with kappa or intra-
correlation coefﬁcient. Three studies adjusted for age, sex and
BMI; the other studies did not correct for BMI-related IGF-1
changes.
Table IIIa
Study characteristics of studies on serum IGF-1 and radiographic OA
Author, year (ref.) N Study design Population Sex Age (years,
mean  SD)
Assessment ROA Adjustments Results on IGF-1 & ROA Quality
Score
Hand Knee Spine Total Age Sex BMI Height Race
Hochberg, 199332 115 Case-control Baltimore Longitudinal
Study of Aging
60 hand OA
55 healthy controls
\ 100% 53.6  18.2 KL e e e Yes NA No No No NS (P  0.50) 57%
McAlindon, 199330 156 Case-control Bristol community survey
78 knee OA
78 healthy controls
\ 60%
_ 40%
71.8  7.6 e TFJ & PFJ
OP & JSN & SCL
e e Yes Yes No No No NS (P 0.48) 64%
Denko, 199439 111 Case-control 57 generalized OA
54 healthy controls
\ 68%
_ 42%
\ 66  12
_ 68  11
e e e JSN & OP Yes Yes No Yes Yes Low IGF-1 P < 0.001 43%
Hochberg, 199433 187 Case-control Baltimore Longitudinal
Study of Aging
59 knee OA
128 healthy controls
\ 38%
_ 62%
\ 54  18
_ 56  17
e KL e e Yes NA No No No NS 64%
Fernihough, 199637 27 Case-control 16 knee OA
11 healthy controls
\ 44%
_ 56%
m69 e ACR criteria e e No No No No No NS 29%
Lloyd, 199631 761 Case-control Chingford study
606 patients with OA
at different locations
155 healthy controls
\ 100% 54.2  6 KL KL KL e Yes NA No Yes No High IGF-1 & DIP
P ¼ 0.006, knee P < 0.001
79%
Fraenkel, 199838 423 Nested
case-control
Framingham OA study
202 knee OA
221 healthy controls
\ 66%
_ 34%
m69.9 e KL e e Yes Yes Yes Yes Yes NS
\ OR 0.9 (0.6e1.7)
_ OR 1.2 (0.6e2.6)
71%
Jubb, 199840 162 Case-control 74 polyarticular OA
37 knee OA
61 healthy controls
\ 100% NA e Not speciﬁed e Not speciﬁed Yes NA No No No NS 14%
ROA ¼ radiological OA; ACR = American College of Rheumatology criteria; KL = Kellgren & Lawrence; OP ¼ osteophytosis; JSN ¼ joint space narrowing; SCL ¼ sclerosis; DIP = distal interphalangeal; PIP ¼ proximal inter-
phalangeal; CMC ¼ carpometacarpal; NA ¼ not applicable; NS ¼ not signiﬁcant; m ¼ mean; TFJ ¼ tibiofemoral joints; PFJ ¼ patellofemoral joint; N ¼ number of studied patients; e ¼ not assessed.
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K.M.J.A. Claessen et al. / Osteoarthritis and Cartilage 20 (2012) 79e86 83Association between serum IGF-1 and radiographic OA
in primary OA patients
The largest study (Lloyd et al., N ¼ 761) showed a positive
association between high serum IGF-1 and radiographic knee OA31.
In this HQ case-control study, a clear doseeresponse relationship
was shownwith the strongest association in patients with bilateral
and more severe knee OA (P < 0.0001). High IGF-1 levels were also
associated with hand OA, especially in the distal interphalangeal
(DIP) joint (P ¼ 0.006). Results were adjusted for age, weight and
height. Fraenkel et al. reported a trend toward signiﬁcance for
higher serum IGF-1 in men with bilateral knee OA, in a HQ longi-
tudinal study with a nested case-control design. Adjustments for
age, sex, BMI, height and race were made30.
In contrast, Denko et al. reported lower serum IGF-1 concen-
tration in patients with general radiographic OA39. In this low-
quality (LQ) case-control study (N ¼ 111; Tables IIIa and b),
patients and controls were matched on age, sex, race, height and
weight.
Five studies (two HQ33,38, three LQ32,37,40), all case-control
studies, reported no association between serum IGF-1 and radio-
graphic OA. Three studies37,38,40 found no relation between serum
IGF-1 and knee OA. In two cross-sectional studies32,33, Hochberg
et al. reported signiﬁcantly lower IGF-1 levels in patients with
radiographic hand and knee OA from the Baltimore Longitudinal
Study of Aging cohort. However, after adjustments for age-related
IGF-1 decline, results were no longer signiﬁcant. None of these
studies corrected for BMI.
By taking the mean of all methodological quality scores as cut-
off point, a study was considered HQ with a score 59%. Using
this alternative cut-off point didn’t change the results. The sensi-
tivity analysis based on all positive studies without quality
assessment, showed similar results with moderate evidence for no
association between serum IGF-1 and radiographic OA, and a posi-
tive association between IGF-1 gene polymorphisms and radio-
graphic OA.
Genetic association between IGF-1 gene polymorphisms and
radiographic OA
Three studies, all HQ studies, provided data on the outcomes of
genetic association studies, in which Single Nucleotide Poly-
morphisms (SNPs) in the IGF-1 and IGF-1 receptor genes were
investigated in relation to radiographic OA. All studies were cross-
sectional; one study contained only women from a Japanese
population27.
Meulenbelt et al. investigated polymorphisms in the promoter
region of the IGF-1 gene in relation to radiographic OA. Nine
different alleles were identiﬁed, of which allele 3 and 4 (A3, A4)
were associated with a higher prevalence of radiographic OA at any
joint site, mostly in the hip. Especially A3, which is less prevalent
than A4, is from a population genetic point the most likely allele
associated with radiographic OA. Subjects heterozygous for A3 had
a 1.9 times increased risk of radiographic OA compared towildtypes
(adjustments for age, sex, BMI and BMD). A 3.6 times increased risk
of radiographic OA was found in patients homozygous for A3,
however non-signiﬁcant26.
Zhai et al. studied the 192bp allele of the IGF-1 promotor poly-
morphism in relation to radiographic OA in the knee, hip, hand and
spine. Cases had at least one of the four joint sites affected. Previ-
ously, absence of 192bp (wildtype) allele was found to be associated
with lower serum IGF-1 levels and lower height41, indicating
functional properties. In the overall study population, the poly-
morphism increased radiographic OA risk, although not statistically
signiﬁcant. In a subgroup aged 65 years radiographic OA risk was
Table IV
Methodological quality scores of the studies, according to study type
1 2 3 4 5 6 7 8 9 10 11 12 13 14 Individual
score
Total
obtainable
Total
score
Longitudinal (nested case-control)
Fraenkel, 1998 0 1 1 0 0 1 1 1 1 1 1 0 1 1 10 14 71%
Case-control
Lloyd, 1996 1 1 1 0 0 1 1 1 1 1 1 1 1 0 11 14 79%
McAlindon, 1993 0 1 1 0 0 1 1 0 1 1 1 1 1 0 9 14 64%
Hochberg, 1994 0 1 1 0 0 1 1 1 0 1 1 1 1 0 9 14 64%
Hochberg, 1993 0 1 1 0 0 0 1 1 0 1 1 1 1 0 8 14 57%
Denko, 1994 1 1 0 0 0 1 1 0 0 0 1 0 1 0 6 14 43%
Fernihough, 1996 0 0 0 0 0 1 1 0 0 0 1 0 1 0 4 14 29%
Jubb, 1998 0 0 0 0 0 1 1 0 0 0 0 0 0 0 2 14 14%
Cross-sectional
Meulenbelt, 1998 1 1 NA 0 NA 1 1 1 0 1 NA 1 1 1 9 11 82%
Zhai, 2004 1 1 NA 0 NA 1 1 1 0 1 NA 1 1 1 9 11 82%
Urano, 2008 0 1 NA 0 NA 1 1 1 0 1 NA 1 1 0 7 11 64%
Each itemwas scored 1 if it met themethodological criteria listed in Table I, if not or otherwise not described, a score of 0 was assigned. Positive scores were summed to give an
overall internal validity score. NA¼not applicable.
K.M.J.A. Claessen et al. / Osteoarthritis and Cartilage 20 (2012) 79e8684signiﬁcantly higher in SNP carriers (P ¼ 0.03 for trend), with
highest prevalence in homozygotes (OR¼ 1.9), suggesting an allele-
dose effect. These ﬁndings were independent of age, sex, BMI and
BMD28.
Urano et al. studied a SNP at intron1 in the IGF-1 receptor gene
(IVS1 þ 14488C > G, rs11247361) in relation to radiographic
features of spinal disc degeneration in healthy postmenopausal
Japanese women, assessed semi-quantitatively by the Genant
method. In this population-based study, the genetic variation was
correlated with spinal disc narrowing (OR ¼ 2.0, P ¼ 0.0033),
especially in homozygotes, suggesting a possible contribution of
IGF-1R to human cartilage metabolism. Occurrence of endplate
sclerosis and osteophytosis was comparable between SNP
genotypes27.
Discussion
A relationship between IGF-1 and radiographic primary OA is
suggested from in vitro and anecdotal evidence, but is infrequently
studied in observational studies. This is the ﬁrst systematic review
that summarizes current data on the relation between radiographic
OA and either serum IGF-1 levels or IGF-1 gene polymorphisms,
taking into account important factors inﬂuencing IGF-1 concen-
tration, such as age, sex and BMI. Using strictly deﬁned criteria,
a total of only eight studies were included that studied serum IGF-1
in relation to radiographic OA. Based on these studies, we can
conclude that there is moderate evidence for no association
between serum IGF-1 and radiographic OA, although there is
moderate evidence for a positive relationship between IGF-1 gene
polymorphisms and radiographic OA.
Only the HQ study of Lloyd et al. showed high serum IGF-1 to be
related with radiographic knee and hand OA, especially in bilateral
and more severe knee OA31. Fraenkel et al. reported a trend for
higher serum IGF-1 levels in men with bilateral knee OA, although
non-signiﬁcant. In contrast, Denko et al. found low IGF-1 levels to
be associated with general radiographic OA39; however, this study
was ranked as low methodological quality. The remaining six
studies (three HQ, three LQ) showed no signiﬁcant relationship.
We were able to include three HQ studies26e28 on genetic
polymorphisms in the GH/IGF-1 pathway in relation to radio-
graphic OA. All three showed associations between IGF-1 gene
polymorphisms and OA, in accordance with the hypothesis that
genetic variations in the GH/IGF-1 system may be involved in OA
pathogenesis. The SNP in the IGF-1 gene promotor region studied inZhai et al., was earlier found to be associated with lower IGF-1
levels and lower body height, suggesting that chronic low IGF-1
levels play a role in the pathophysiology of primary OA41.
However, the exact role of the IGF-1 polymorphism in the GH/IGF-1
pathway has not yet been elucidated. The other SNPs26,27 were not
studied in relation to circulating IGF-1 levels. Furthermore, we have
to take into account interactions between polymorphisms. Zhai
et al. studied the interaction with a collagen type II A1 (COL2A1)
polymorphism, which is associated with an extreme OA pheno-
type29. Highest OA prevalence was found in individuals with both
IGF-1 and COL2A1 risk phenotype, suggesting that the IGF-1 effect
occurs in interaction with the COL2A1 gene28.
Our review may suffer from several limitations. Firstly, the
review is based mainly on cross-sectional data and therefore the
strength of evidence is limited by the quality of the available
studies. Unfortunately, only one longitudinal study (nested case-
control study)38, investigated OA incidence in relation to serum
IGF-1. There was an additional longitudinal study44 on IGF-1 and
radiographic OA, though this study focuses on OA progression and
was therefore excluded. In this 12-year follow-up study, Schouten
et al. found high serum IGF-1 levels to be a risk factor for knee OA
progression, especially of osteophytosis, independently of age, sex
and BMI. Because the progression data could underline ﬁndings on
prevalent and incident OA, more research is needed on the rela-
tionship between serum IGF-1 and primary OA progression.
Secondly, we cannot rule out publication bias, especially in the
genetic ﬁeld, which can be explained by a selection of positive
studies for publication. Thirdly, small study sizes may inﬂuence the
ﬁndings, especially since the IGF-1 concentration is affected by
many factors that also inﬂuence OA risk. Finally, there is a possi-
bility of misclassiﬁcation of OA by inclusion of conventional
radiographs only, which may contribute to not ﬁnding a consistent
association between IGF-1 and radiographic OA. Magnetic reso-
nance imaging (MRI) may give additional information to plain
ﬁlms, however at this moment no MRI studies have investigated
the relationship between IGF-1 and OA.
Several sources of between-study heterogeneity can be identi-
ﬁed. First of all, the study design can lead to heterogeneity.
Secondly, assessing the role of IGF-1 in OA by serum samples is very
complex, because individual IGF-1 levels are liable to temporal
variations. Furthermore, IGF-1 levels are inversely correlated to age,
estrogen levels and BMI9,42,43, so adjustments for these factors are
essential for interpretation of IGF-1 levels. Most studies corrected
for age and sex, however, only three adjusted for BMI. In addition,
K.M.J.A. Claessen et al. / Osteoarthritis and Cartilage 20 (2012) 79e86 85RIAs for measuring serum IGF-1 are subject to analytical difﬁculty.
This means that large sample sizes are required for demonstrating
an IGF-1 effect on radiographic OA at population level; unfortu-
nately, only the study of Lloyd et al.31 reported a large sample size
(N ¼ 761). Another remaining problem is OA case deﬁnition. For
epidemiological studies, there is general consensus that radiolog-
ical features are the preferred method. However, the included
studies used different scoring methods (KL, Ahlback, ACR criteria)
at different joint sites.
Because of heterogeneity of several study aspects, no meta-
analysis could be performed. We provided an alternative by per-
forming a best-evidence synthesis and methodological quality
assessment, although no generally accepted criteria set exist for
methodological quality assessment in observational studies and for
performing a best-evidence synthesis. Lievense et al. presented
a reproducible criteria list for methodological quality assessment,
which we modiﬁed to cover our review topic36. The use of quality
scores could be a technical limitation of our review at the same
time, because using different criteria sets could result possibly in
different interpretation of our results. According to our criteria set
(Tables IIIa and b), four of the eight studies on serum IGF-1 and all
three genetic association studies were considered as HQ studies.
Knowledge of the association between serum IGF-1 levels and
radiographic OA is very important, because this could increase our
understanding of the pathogenesis of OA, which subsequently
could lead to development of new treatment options.
An important question that needs further research is whether
circulating total IGF-1 levels truly reﬂect tissue concentrations.
Preliminary data indicate that measuring free unbound IGF-1 levels
and IGF-1 bioactivity better reﬂect GH/IGF-1 status than serum
total IGF-145e47. Free IGF-1 is the major biologically active form of
IGF-1; however, because of methodological difﬁculties in
measurement, total serum IGF-1 is often used to assess GH/IGF-1
axis activity45. This could possibly explain not ﬁnding a consistent
effect of total IGF-1 on radiographic OA.
In conclusion, in vitro studies, genetic association studies and the
high secondary risk in pathological IGF-1 states suggest all effects of
the GH/IGF-1 system in OA development. Although the largest cross-
sectional study31 and the longitudinal study on OA progression44
found a positive association with high serum IGF-1, inconsistent
results were shown in studies on serum IGF-1 and radiographic OA.
This systematic review concludes that there is moderate evidence
that IGF-1 is no risk factor for primary radiographic OA. Since we
cannot exclude that methodology, publication bias and small sample
size of the available studies have inﬂuenced the results, we suggest
that future well-designed large prospective studies are needed to
strengthen the evidence for the role of IGF-1 in primary OA.
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